FC084CSA / FindCure Biosci - LARVOL DELTA

A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors (clinicaltrials.gov) - P1/2 | N=33 | Recruiting | Sponsor: FindCure Biosciences (ZhongShan) Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor

A Study of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid Tumors (clinicaltrials.gov) - P1 | N=21 | Completed | Sponsor: FindCure Biosciences (ZhongShan) Co., Ltd. | Active, not recruiting ➔ Completed | N=43 ➔ 21 | Trial primary completion date: Dec 2024 ➔ Mar 2025

Enrollment change • Trial completion • Trial primary completion date • Solid Tumor

A Study of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid Tumors (clinicaltrials.gov) - P1 | N=43 | Active, not recruiting | Sponsor: FindCure Biosciences (ZhongShan) Co., Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • Metastases • Oncology • Solid Tumor

A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors (clinicaltrials.gov) - P1/2 | N=33 | Not yet recruiting | Sponsor: FindCure Biosciences (ZhongShan) Co., Ltd.

Combination therapy • Metastases • New P1/2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Phase I clinical study of FC084CSA, a high selective AXL kinase inhibitor that ameliorates tumor microenvironment and augments the effectivity of immunotherapy. (ASCO 2024) - P1 | "AXL inhibitor bemcentinib (formerly BGB324) has been found to improve the effectiveness of immunotherapy of immune checkpoint inhibitors. FC084CSA was well tolerated in patients with previously heavily treated solid tumors. Clinical trial information: NCT06231550."

Biomarker • Clinical • IO biomarker • P1 data • Tumor microenvironment • Anemia • Hematological Disorders • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Disease • Solid Tumor • AXL • STK11

A Study of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid Tumors (clinicaltrials.gov) - P1 | N=43 | Recruiting | Sponsor: FindCure Biosciences (ZhongShan) Co., Ltd.

New P1 trial • Oncology • Solid Tumor